InVivo Therapeutics Holdings Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVIVQ research report →
Companywww.invivotherapeutics.com
InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI).
- CEO
- Richard M. Toselli
- IPO
- 2010
- Employees
- 6
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $1.15M
- P/E
- -0.05
- P/S
- 0.00
- P/B
- 0.03
- EV/EBITDA
- 1.46
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -60.12%
- ROIC
- -63.58%
Performance & Tape
- 52W High
- $1.41
- 52W Low
- $0.15
- 50D MA
- $0.38
- 200D MA
- $0.56
- Beta
- 0.37
- Avg Volume
- 8.13K
Get TickerSpark's AI analysis on NVIVQ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our NVIVQ Coverage
We haven't published any research on NVIVQ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NVIVQ Report →